Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is defined by the degeneration of nigral dopaminergic (DA) neurons and can be caused by monogenic mutations of genes such as parkin. The lack of phenotype in parkin knockout mice suggests that human nigral DA neurons have unique vulnerabilities. Here we generate induced pluripotent stem cells from normal subjects and PD patients with parkin mutations. We demonstrate that loss of parkin in human midbrain DA neurons greatly increases the transcription of monoamine oxidases and oxidative stress, significantly reduces DA uptake and increases spontaneous DA release. Lentiviral expression of parkin, but not its PD-linked mutant, rescues these phenotypes. The results suggest that parkin controls dopamine utilization in human midbrain DA neurons by enhancing the precision of DA neurotransmission and suppressing dopamine oxidation. Thus, the study provides novel targets and a physiologically relevant screening platform for disease-modifying therapies of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD patient iPSC-derived dopaminergic neurons harboring Parkin mutation displayed decreased microtubule stability, increased oxidative stress, reduced dopamine uptake, and increased spontaneous dopamine release [36,37].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“In sharp contrast to the situation seen in PD patients with parkin mutation”
ResultParkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 1×
“Parkin mutations did not significantly affect mitochondria We examined whether the loss of parkin significantly affect mitochondria by treating the four lines of iPSC-derived neurons without or with CCCP (10 μM for 16 h) to induce mitophag”
BackgroundHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
MONOAMINE OXIDASE: From Genes to Behavior
Shih, J. C., Chen, K., & Ridd, M. J. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.197 · Cited by 1,206 · cited 1×
“, which are mitochondrial enzymes responsible for the oxidative deamination of dopamine , a reaction that produces large quantities of reactive oxygen specie”
BackgroundHu, B.-Y., Weick, J. P., Yu, J., Ma, L.-X., Zhang, X.-Q., Thomson, J. A., & Zhang, S.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910012107 · Cited by 1,013
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971
Research works printed but not linked: 1
- Chambers SM Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nat Biotechnol 27 275 280 2009 19252484 PMC2756723
Cited by
Items 201–252 of 252
Gopurappilly, R. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_643 · Cited by 5
Bury, A. G., Olejnik, A., Tocco, C., Saurat, N. G., Stephen, E., Hockemeyer, D. F., Schwamborn, J. C., Studer, L., Mastroberardino, P. G., Bolognin, S., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01137-2 · Cited by 6
“Lineage-determining transcription factors can be used to repro-gramme somatic cells into subtype-speci fi c neurons, including DA neurons 111,143,146 .”
dos Santos, L. R., Duplan, E., Debord, J., Fremont, G., Minniti, J., Lauritzen, I., Mutez, E., Leghay, C., Chartier‐Harlin, M., Checler, F., et al. (2026) · Autophagy · doi:10.1080/15548627.2026.2669458 · Cited by 3
iPSC for modeling of metabolic and neurodegenerative disorders
Valadez-Barba, V., Cota-Coronado, A., Barragán-Álvarez, C. P., Padilla‐Camberos, E., & Diaz-Martinez, N. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823882-0.00007-2 · Cited by 3
McDonald, K. O., Lyons, N. M. A., Gray, L. K. C., Xu, J. B., Schoderboeck, L., Hughes, S. M., & Basak, I. (2024) · Cells · doi:10.3390/cells13121016 · Cited by 6
“Briefly, the iDAs were maintained for 21 days in their respective media (as mentioned in Section 2.1), and on day 21, media were collected for the ELISA from iDAs with no KCl treatment and iDAs treated with 56 mM KCl for 15 min (following [29]).”
MethodInfluentialSong, P., Franchini, R., Chen, C., Duong, B., Wang, Y., Savas, J. N., Parisiadou, L., & Krainc, D. (2025) · Research Square · doi:10.21203/rs.3.rs-6298077/v1 · Cited by 3
SHARMA, A. K., Atasi, T., Collin, F., Wang, W., Lam, T. T., García-Milian, R., Arroum, T., Pham, L., Hüttemann, M., & Moszczyńska, A. (2025) · Biomolecules · doi:10.3390/biom15070958 · Cited by 3
Dopamine neurotransmission in Parkinson's disease
Cramb, K. M. L., Noor, H., Wade‐Martins, R., & Cragg, S. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00012-9 · Cited by 2
Enderami, S. E., BOJNORDI, H. M. N., & Pasandi, M. S. (2023) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2023_040 · Cited by 2
Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases
Kumar, S., Narayanan, K., Mishra, S., Padmanabhan, P., Radda, G. K., & Gulyás, B. Z. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1232-4 · Cited by 2
Filippich, C., Wolvetang, E. J., & Mowry, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt103 · Cited by 4
Modeling Parkinson Disease with Human Induced Pluripotent Stem Cells
Lü, J. (2014) · Cloning & Transgenesis · doi:10.4172/2168-9849.1000e113 · Cited by 2
“With the development of PD studies and pre-clinical cell therapeutic exploration using iPSCs [5,20,27-33], more efficient and effective treatments for PD are expected in the near future.”
BackgroundLoss of PINK1 or Parkin Function Results in a Progressive Loss of Mitochondrial Function
Taanman, J., & Protasoni, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812146-7.00007-x · Cited by 2
Introduction and Basic Concepts in Stem Cell Research and Therapy: The Facts and the Hype
Essawy, M., Shouman, S., Magdy, S., Abdelfattah‐Hassan, A., & El‐Badri, N. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-55359-3_1 · Cited by 2
Ndayisaba, A., Herrera-Vaquero, M., Wenning, G. K., & Stefanova, N. (2019) · Clinical Autonomic Research · doi:10.1007/s10286-019-00614-y · Cited by 4
Lehtonen, Š., Lehtonen, M., & Koıstınaho, J. (2016) · InTech eBooks · doi:10.5772/62851
Dopamine and Early Onset Parkinson’s Disease
Wize, K., Kozubski, W. P., & Dorszewska, J. (2018) · InTech eBooks · doi:10.5772/intechopen.80400 · Cited by 1
“There is also a suggestion about a role in DA utilization in human dopaminergic neurons by controlling the precision of dopaminergic neurotransmission and DA oxidation [34].”
BackgroundModeling the pathophysiology of Parkinson’s disease in patient-specific neurons
Feng, J. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220961788 · Cited by 2
“To understand the functions of parkin in human midbrain DA neurons, we generate induced pluripotent stem cells (iPSCs) from PD patients with parkin mutations and normal subjects.(45) In iPSC-derived human midbrain DA neurons, parkin mutations disrupt the precision of dopaminergic transmission by increasing spontaneous…”
BackgroundIdentification of potential Parkinson’s disease biomarkers using computational biology approaches
Chowdhury, H. A., Barah, P., Bhattacharyya, D. K., & Kalita, J. K. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-020-00280-5 · Cited by 1
Induced pluripotent stem cell derived from postmortem tissue in neurodegenerative disease research
Rogers, J., Myers, A., & Dykxhoorn, D. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822135-8.00008-2 · Cited by 1
Recovery from Parkinsonism with N-acetylcysteine-differentiated neurons
Noh, Y. H., Kim, J. Y., Kim, D. H., Kim, O. H., Park, J., Kee, B. S., Sohn, D. S., Chung, Y. H., Kim, K. Y., Lee, W. B., et al. (2013) · Molecular Biology · doi:10.1134/s0026893313040183
“They are suitable for cell therapy of PD, as they can prevent immune rejection and also avoid ethical problems of using ESCs [14].”
Patient-Specific Induced Pluripotent Stem Cell Models of Parkinson’s Disease
Liao, M.-C. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4529
“PARK2 exon deletions (Jiang et al., 2012) 2 patients & 2 CTLS dermal fibroblast Lenti- OSKN Increased oxidative stress and enhanced activity of Nrf2 pathway, exhibited abnormal mitochondrial morphology & Increased spontaneous DA release, reduced DA uptake and DAT-binding sites, elevated ROS by increasing MAO transcrip…”
BackgroundThe Role of Parkin in Parkinson’s Disease: A Stem Cell Perspective
Feng, J. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.25 · Cited by 1
“The landmark discovery of induced pluripotent stem cells (iPSC) [5, 6] has made it possible for us to generate patient-specific midbrain DA neurons from PD patients with parkin mutations and normal controls [7].”
BackgroundDisease Modeling and Drug Discovery Using Human Pluripotent Stem Cells
Honoré, C., & Hansson, M. D. (2013) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4614-8066-2_15
Systemic and Cell-Type Specific Profiling of Molecular Changes in Parkinson`s Disease
Lee, Y. (2012) · Interdisciplinary Bio Central · doi:10.4051/ibc.2012.4.3.0006
Zebrafish as a translational model of Parkinson's disease : a study of microRNAs
Trollope, L. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Al-Baradie, R. S., Lynch, S., Borresen, J., Krupiński, J., & SLEVIN, M. A. (2013) · Majmaah Journal of Health Sciences
Humane Stammzellen: eine Perspektive für den Morbus Parkinson?
Schlachetzki, J. C. M., & Winkler, J. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0892-4
“Parkin [12, 13] — Heterozygote/Homozygote Deletionen von”
Induced Pluripotent Stem Cells (iPSCs) to Study and Treat Movement Disorders
Datta, D., & Kim, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00009-3
Stem cells in Parkinson’s disease: an updatePreprint
Gollamudi, S. (2016) · doi:10.15200/winn.148233.37308
Prasad, K. N. (2016) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-33486-8_15
Stem Cells and Neurogenesis for Brain Development, Degeneration and Therapy
Peer, J., Zhang, H., Peng, H., Vance, K. E., Huang, Y., & Zheng, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_15
5 Stem Cells for Parkinson’s Disease
Lamba, D. A. (2017) · CRC Press eBooks · doi:10.1201/9781315402185-6
Eren, E., Erkan, E. P., Genç, Ş., & Genc, K. K. (2017) · Stem cells in clinical applications · doi:10.1007/978-3-319-59165-0_2
“For instance, increased monoamine oxidase (MAO) activity was observed in PARK2 mutant iPSC-derived dopaminergic neurons, and cells showed increased dopamine release and decreased uptake (Jiang et al. 2012).”
Joshi, P. K., Neely, M. D., & Bowman, A. B. (2018) · Wiley eBooks · doi:10.1002/9781119283249.ch7
From Zero to Neuro-Reprogramming: Innovations in Translational Neuroregenerative Medicine
Galuta, A., & Tsai, E. C. (2019) · University of Ottawa Journal of Medicine · doi:10.18192/uojm.v9i1.4163 · Cited by 1
Varderidou, S. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1458
Models of Neurodegenerative Diseases
Maharjan, N., & Saxena, S. (2022) · Learning materials in biosciences · doi:10.1007/978-3-031-07793-7_10 · Cited by 1
Roles of Ipsc in Advancing Treatments for Neurological DisordersPreprint
Zhang, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4818803
Genome Editing and Human-Induced Pluripotent Stem Cells Facilitate Parkinson’s Disease Modeling
Polanco, C. M., Inzunza, J., Nalvarte, I., & Arias, J. (2025) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-94101-6_3
Tremblay, C., Pshevorskiy, L., Cottez, R. J., Denis, H. L., Émond, V., Morissette, M., Rajput, A. H., Paolo, T. D., Rajput, A., & Calon, F. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01371-2
Yokota, M., Kakuta, S., Shiga, T., Ishikawa, K.-I., Okano, H., Hattori, N., Akamatsu, W., & Koike, M. (2021) · Figshare · doi:10.6084/m9.figshare.14303019
Yokota, M., Kakuta, S., Shiga, T., Ishikawa, K.-I., Okano, H., Hattori, N., Akamatsu, W., & Koike, M. (2021) · Figshare · doi:10.6084/m9.figshare.14303022
Yokota, M., Kakuta, S., Shiga, T., Ishikawa, K.-I., Okano, H., Hattori, N., Akamatsu, W., & Koike, M. (2021) · Figshare · doi:10.6084/m9.figshare.14303016
Knappe, E., Händler, K., Streubel-Gallasch, L., Rudolph, F., Alvarez‐Fischer, D., Cowley, S. A., Grünewald, A., Spielmann, M., Klein, C., & Seibler, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.27.714690
“Work with iPSC-derived DA neurons from PD patients harboring mutations in PRKN revealed its role in mitochondrial function and biogenesis [8–12], mitophagy [13, 14], DA homeostasis [15, 16], calcium homeostasis [17], and inflammation [18].”
Modelling Parkinson's disease with patient induced pluripotent stem cells
Thamrin, N. P. (2022) · theses.fr (ABES) · doi:10.70675/2021f43cz12b4z4d3eza533zba4392d2ad4d
dos Santos, L. R. (2023) · theses.fr (ABES) · doi:10.70675/af8ecae9z4b9ez49b2zab71z84776f0e4807
Burdman, G., Hanna, M., Yndart, A., Vashist, A., & Lakshmana, M. K. (2026) · Cells · doi:10.3390/cells15191768 · Cited by 1
“Those carrying PARK2 and PINK1 [96–99], LRRK2 [100,101], and SNCA–A53T mu‑ tation [102,103] have been demonstrated to exhibit typical PD‑like pathological features, including selective accumulation of α ‑synuclein inclusions, defects in mitochondrial au‑ tophagy, increased sensitivity to oxidative…”
HONG, Y., Ming, G.-L., & SONG, H. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19043-8.00002-5
Parkin mediated mitochondrial quality control in central dopamine neurons
Hawong, H.-Y. (2014) · Michigan State University Libraries · doi:10.25335/m5ph73
Metadata
- Authors
- Jiang, H., Ren, Y., Yuen, E. Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., & Feng, J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Roswell Park Comprehensive Cancer Center (US)
- Tottori University (JP)
- Corresponding author
- Feng, Jian
- Venue
- Nature Communications
- Published
- 2012-02-07
- Volume
- 3
- Issue
- 1
- Pages
- 668-668
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3498452
- OpenAlex
- W2010478595
- Cited by
- 254
- References
- 39
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 19 · 2021: 20 · 2020: 16 · 2019: 26 · 2018: 24 · 2017: 16 · 2016: 24 · 2015: 17 · 2014: 18 · 2013: 24 · 2012: 15
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Roswell Park Cancer Institute
- State University of New York
- New York State Stem Cell Science
- National Natural Science Foundation of China (30928006)
- National Institutes of Health (5rc2ns070276-02, NS070276)
- U.S. Public Health Service (C024406)
- National Institute of Mental Health (R25MH077823)
- National Institute on Drug Abuse (R01DA026947)
- National Institute of Neurological Disorders and Stroke (RC2-NS070276, NS061856, R01NS061856, NS071122, NS070276, R01NS071122)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkin, Parkinson's disease, dopaminergic neurons, midbrain, dopamine uptake, dopamine release, monoamine oxidase, oxidative stress, induced pluripotent stem cells, parkin mutations, ubiquitin ligase, disease-modifying therapy
- MeSH terms
- Animals, Binding Sites, Brain, Dopamine, Fibroblasts, Gene Expression Regulation, Humans, Mitochondria, Models, Biological, Monoamine Oxidase, Mutation, Neurons, Oxygen, Parkinson Disease, Phenotype, Skin, Time Factors, Oxidative Stress, Ubiquitin-Protein Ligases, Mice, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.